Vectura | Sustainability Performance
Develops and markets inhalation products and devices for respiratory diseases.
1997
United Kingdom
201 - 500 employees
Pharmaceuticals
$100M - 500M in revenue
Sustainability Ranking & Industry Benchmark
#4483
Overall#602
in United Kingdom#104
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Controversy level
- The company, a developer of inhaled medicines for respiratory diseases such as asthma and chronic obstructive pulmonary disease, was acquired by tobacco company Philip Morris International in 2021, a takeover widely condemned by the medical and publichealth community (including the British Medical Association, the European Respiratory Society and Asthma UK) as a profound conflict of interest, since a cigarette maker would profit from treating diseases caused by smoking, leading several research bodies and hospitals to cut ties with the company.
